Clinical Trial

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Telitacicept in patients with IgA nephropathy. The control group will be observed for up to 6months without administration of Telitacicept. This Single center, Randomized, Open Label, Comparative study will evaluate the effect and safety of and Standard treatment for 6months in IgA Nephropathy.
Trial Details
NCT Number NCT07098897
Lead Sponsor The Affiliated Hospital of Xuzhou Medical University
Conditions IgA Nephropathy (IgAN)
Enrollment 150 participants
Start Date 2024-08-01
Primary Completion 2025-05-25 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-01